Dailipharma
ActiveSummary
The computed 12-month bankruptcy probability of Dailipharma is 1.8% (moderate). The 2025 annual accounts show equity of €74,467 and a net result of €3,297. Equity is growing by about 16% per year across the filed financial years. Its solvency ranks better than 40% of 21,983 sector peers (NACE 47, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
28-08
Gazette deed
Appointment: Jan Helskens Consulting (director)Permanent representative: HELKSENS Jan · Kind of shares · Share issue18 facts ▸
- General meeting, 03-08-2026
- Other provision, “Verslaggeving, EERSTE BESLISSING” (deed in Dutch)
- Other provision, “Splitsing van de aandelen, TWEEDE BESLISSING” (deed in Dutch)
- Kind of shares, “onderscheiden rechten op het vlak van de verdeling van de winst, DERDE BESLISSING” (deed in Dutch)
- Share issue, “B-Aandelen”, 150000 (deed in Dutch)
- Capital contribution
- Other provision, “Inschrijving op en volstorting van de nieuwe aandelen”, EUR (deed in Dutch)
- Financial instrument, “aandelenoptieplan van de Vennootschap”, 23684 (deed in Dutch)
- Share issue, “B-Aandelen, zelfde aard en rechten als bestaande B-Aandelen” (deed in Dutch)
- Power of attorney (3 times)
- Name change, Dailipharma
- Purpose change
- +6 further facts in this act
16-07
Gazette deed
Resignation: Louis VANHOVE (director)2 facts ▸
- General meeting, “enige aandeelhouder, De aandeelhouders” (deed in Dutch)
- Director resignation, Louis VANHOVE (director)
05-05
Gazette deed
Registered officeRegistered-office move2 facts ▸
- General meeting, 19-01-2026
- Registered-office move, Doorniksestraat 27, 8500 Kortrijk
About the unread acts
Of the 6 Belgian Official Gazette deeds we know for this company, 3 have been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.